Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Peter Higgins, MD, on The Impact of Baseline Disease Characteristics on Clinical Outcomes of Upadacitinib

Dr Higgins gives a recap of his poster presentation at Digestive Disease Week 2022 on evaluating the impact of baseline ulcerative colitis characteristics on clinical outcomes following treatment with upadacitinib.


Peter Higgins, MD, PhD, is the director of the IBD Program at the University of Michigan.

© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the AIBD Network or HMP Global, its employees, and affiliates. 

Advertisement

Advertisement

Advertisement